SCHEMBL5541823

SCHEMBL5541823

O=COCc1cccc(C(F)(F)C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.46
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCD Q05655 1/20 0.43
MAOB P27338 8/20 0.40
NR4A2 P43354 2/20 0.40
MMP1 P03956 1/20 0.37
MMP12 P39900 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
ACP3 P15309 1/20 0.37
MAOA P21397 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PGK1 P00558 1/20 0.36
PGK2 P07205 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351100 0.87 IDO1 (0.62) IDO1MAPTPOLBPRKCAPRKCD
SCHEMBL11394076 0.82 MAOB (0.39) IDO1MAOBMAOA
SCHEMBL5540230 0.80 IDO1 (0.40) IDO1MAOB
SCHEMBL9256367 0.78 SOD1 (0.40) IDO1MAPTPOLBPRKCAPRKCD
SCHEMBL5541818 0.77 IDO1 (0.46) IDO1MAPTPOLBPRKCAPRKCD
SCHEMBL18378024 0.75 ACP3 (0.43) IDO1MAPTMAOBACP3TAAR1
SCHEMBL5545881 0.75 CHRM2 (0.43) IDO1MAPTPOLBMAOBNR4A2
SCHEMBL2095988 0.74 CHRM2 (0.55) MAOBFFAR4
SCHEMBL5543363 0.74 ADH1B (0.50) FFAR1FFAR4ACP3TAAR1L3MBTL1
SCHEMBL95134 0.74 IDO1 (0.58) IDO1MAOBNR4A2MMP1MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IDO1 3181/4885MAPT 4117/4885POLB 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.